[1]Kamisawa T,Wood LD,Itoi T,et al.Pancreatic Cancer[J]. Lancet, 2016, 388:73-85. [2]魏超,张晓,高杰.长链非编码RNA与mRNA在胰腺癌中的差异表达及其预后价值[J].癌变·畸变·突变,2019,31:119-126+132. [3]Chen W, Zheng R, Baade PD,et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66:115-132. [4]Chen W,Sun K,Zheng R,et al. Cancer incidence and mortalityin China,2014[J]. Chin J Cancer Res,2018,30: 1-12. [5]Inoue K, Maeda N, Mori T,et al. Possible involvement of Opa-interacting protein 5 in adipose proliferation and obesity[J]. PLoS One 2014; 9: e87661. doi: 10.1371/journal.pone.0087661. [6]He X, Ding X, Wen D,et al. Exploration of the pathways and interaction network involved in bladder cancer cell line with knockdown of Opa interacting protein 5[J]. Pathol Res Pract, 2017,213: 1059-1066. [7]Wang J, Liu X, Dou Z, et al. Mitotic regulator Mis18beta interacts with and specifies the centromeric assembly of molecular chaperone holliday junction recognition protein (HJURP)[J]. J Biol Chem, 2014, 289: 8326-8336. [8]KiM TW,Lee SJ,Park YJ,et al. Opa-interacting protein 5 modulates docetaxel-induced cell death via regulation of mitophagy in gastric cancer[J]. Tumour Biol, 2017, 39: 1010428317733985. doi: 10.1177/1010428317733985. [9]Li HC, Chen YF, Feng W,et al.Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway[J]. Gene, 2017, 603: 1-8. [10]Zheng YQ,Cui YR,Yang S,et al.Opa interacting protein 5 promotes metastasis of nasopharyngeal carcinoma cells by promoting EMT via modulation of JAK2/STAT3 signal[J].Eur Rev Med Pharmacol Sci,2019, 23: 613-621. [11]Gong M, Xu Y, Dong W, et al. Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma[J]. Acta Histochemica, 2013, 115: 810-815. [12]Chun HK, Chung KS, Kim HC, et al. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers[J]. BMB Rep, 2010, 43: 349-354. [13]Nakamura Y, Tanaka F, Nagahara H, et al. Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer[J]. Ann Surg Oncol, 2007, 14: 885-892. [14]Yazarloo F, Shirkoohi R, Mobasheri MB, et al. Expres-sion analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern[J]. Med Oncol, 2013, 30: 368.doi: 10.1007/s12032-012-0368-8. [15]Koinuma J, Akiyama H, Fujita M, et al. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis[J]. Cancer Sci, 2012, 103: 577-586. [16]Li H, Zhang J, Lee MJ, et al. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and beta-catenin signaling pathways[J]. Oncotarget, 2017, 8: 18129-18144. [17]Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interac-tive analyses[J]. Nucleic Acids Res, 2017, 45: W98-W102. [18]Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors[J]. Science, 2002, 295: 868-872. [19]Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR[J]. Nucleic Acids Res, 2001, 29: 2002-2007. [20]Williams JM, Chen GC, Zhu L, et al. Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth[J]. Mol Microbiol, 1998, 27: 171-186. [21]Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy[J]. Oncotarget, 2015, 6: 15772-15787. [22]Fu J, Luo B, Guo WW, et al. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro[J]. Int J Clin Exp Pathol, 2015, 8: 7786-7797. [23]Hu GW, Wu L, Kuang W, et al. Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway[J]. Gene, 2017, 610:24-31. [24]He X, Hou J, Ping J, et al. Opa interacting protein 5 acts as an oncogene in bladder cancer[J]. J Cancer Res Clin Oncol, 2017,143:2221-2233. [25]He X, Ding X, Wen D, et al. Exploration of the pathways and interaction network involved in bladder cancer cell line with knockdown of Opa interacting protein 5[J]. Pathol Res Pract, 2017, 213: 1059-1066. [26]Li HC, Chen YF, Feng W, et al. Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway[J]. Gene, 2017, 603:1-8. [27]Mobasheri MB, Shirkoohi R, Modarressi MH. Cancer/testis OIP5 and TAF7L genes are up-regulated in breast cancer[J]. Asian Pac J Cancer Prev, 2015, 16: 4623-4628. [28]Inoue K, Maeda N, Mori T, et al. Possible involvement of Opa-interacting protein 5 in adipose proliferation and obesity[J]. PLoS One, 2014, 9: e87661.doi: 10.1371/journal.pone.0087661. [29]Kim TW, Lee SJ, Park YJ, et al. Opa-interacting protein 5 modulates docetaxel-induced cell death via regulation of mitophagy in gastric cancer[J]. Tumour Biol, 2017, 39: 1010428317733985. doi: 10.1177/1010428317733985. |